This trial will test how well a combination of lenvatinib and pembrolizumab works in Black participants compared to the efficacy reported in the historical trials.
- Recurrent Endometrial Cancer
- Endometrial Cancer
- Mismatch Repair Proficient
1 Primary · 3 Secondary · Reporting Duration: up to 30 days (plus or minus 15 days) following last dose of study treatment
Side Effects for
1 Treatment Group
Pembrolizumab & Lenvatinib
1 of 1
100 Total Participants · 1 Treatment Group
Primary Treatment: Lenvatinib · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · Female Participants · 15 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Does this trial currently have openings for participants?
"Affirmative. Per the information on clinicaltrials.gov, this medical trial is currently in search of prospective participants and was initially posted on April 1st 2022 before being renewed on April 5th 2022. A total of 100 patients are needed from a single location." - Anonymous Online Contributor
Has the FDA sanctioned Lenvatinib for clinical use?
"Lenvatinib's safety ratings is 2; this score has been assigned as Phase 2 trials have provided some data to confirm the drug's safe usage, yet no evidence exists to suggest efficacy." - Anonymous Online Contributor
What is the current enrollment count for this clinical experiment?
"Affirmative. According to the clinicaltrials.gov website, this medical trial is currently recruiting patients who first registered on April 1st 2022 and the project has recently been updated as of May 4th 2022. This experiment requires 100 participants and will take place at one site." - Anonymous Online Contributor